sellWeak cluster of 710b5-1 plan
Patrick Lamy sold $108k of AKRO
Senior VP, Commercial Strategy at Akero Therapeutics, Inc.. 2,000 shares at an average of $54.14, traded Jun 16, 2025, filed Jun 20, 2025.
Warning score
5Value
$108k
2,000 shares
Holdings after
32,573
-6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +10Trade size$108k at market
- 0Share of holdings soldSold 5.8% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-088206, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 16, 2025 | MOption exercise Common Stock10b5-1 | +2,000 | $19.87 | $40k | 34,573 | Jun 20, 2025 |
| Jun 16, 2025 | SOpen-market sale Common Stock10b5-1 | -1,500 | $53.82 | $81k | 33,073 | Jun 20, 2025 |
| Jun 16, 2025 | SOpen-market sale Common Stock10b5-1 | -500 | $55.09 | $28k | 32,573 | Jun 20, 2025 |
| Jun 16, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 64,182 | Jun 20, 2025 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $542k 10,000 shares | -10% | |
| 44Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $80k 1,453 shares | -1% | |
| 39Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $90k 1,633 shares | -2% | |
| 46Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $90k 1,634 shares | -3% | |
| 37Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $62k 1,129 shares | -1% | |
| 37Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $48k 875 shares | -3% | |
| 36Weak | Akero Therapeutics, Inc. | Scott A. Gangloff Chief Technology Officer | $47k 848 shares | -3% | |
| 55Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $363k 6,620 shares | -1% | |
| 46Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $135k 2,493 shares | -1% | |
| 37Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $50k 919 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.